You are here

Reduced gluten cereal grains

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42DK097976-02
Agency Tracking Number: R42DK097976
Amount: $1,270,952.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-03-01
Award End Date (Contract End Date): 2017-08-31
Small Business Information
4222 E THOMAS RD STE 245
Phoenix, AZ 85018-7609
United States
DUNS: 135964760
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CHARLES MOEHS
 (206) 903-0262
 max.moehs@arcadiabio.com
Business Contact
 CHARLES MOEHS
Phone: (206) 903-0262
Email: max.moehs@arcadiabio.com
Research Institution
 TULANE UNIVERSITY OF LOUISIANA
 
6823 ST. CHARLES AVE
NEW ORLEANS, LA 70118-5665
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a complex mixture of proline and glutamine rich seed storage proteins found in wheat barley and rye Because these proteins are resistant to digestion they persist in the gastrointestinal tract and cause an auto inflammatory response in susceptible individuals Currently the only treatment for these conditions is the maintenance of a strict glute free diet This proposal will test the safety of reduced gluten RG cereal grains using barley a a model cereal in combination with a gluten degrading enzyme supplement in a non human primate model of celiac disease the rhesus macaque Rhesus macaques have been shown to develop a condition that is analogous to human celiac disease when gluten is included in their diet and the condition improves upon gluten withdrawal In ongoing research the PI has been identifying low gluten variants of barley and wheat while the academic collaborators have been developing the animal model of celiac disease and a gluten degrading protease supplement respectively Eliminating all gluten from the diet can be difficult for those suffering from CD or
GS and the use of a gluten degrading supplement by itself is not intended to permit these groups to resume unrestricted gluten consumption We believe that a synergistic therapy combining reduced gluten grains with a gluten protease supplement may provide the opportunity for these individuals to introduce limited quantities of reduced gluten cereals into their diets Testing this hypothesis in a non human primate model is the objective of the proposed research The commercial outcome of this proposal will be reduced gluten variants of barley for which there will be increased assurance of acceptability for multiple food products RG barley represents a new category of cereal grain that may play a role in providing an alternative to the gluten free diet for CD and GS individuals in combination with other therapies The wide adoption of RG barley and other RG grains could ultimately reduce the incidence of these conditions Basic knowledge about the seed characteristics of RG barley may pave the way for RG wheat PUBLIC HEALTH RELEVANCE Celiac Disease is a common intestinal inflammatory condition that affects about of the population and it is increasing in incidence It is triggered by proteins in barley wheat and rye Similarly non celiac gluten sensitivity is triggered by the sam proteins and it too seems to be increasing in incidence We are proposing to develop reduced gluten barley varieties that may serve as components of an alternative to the gluten free diet for these individuals

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government